Hemostemix Inc HMTXF

Primary Symbol: V.HEM

Healthcare Biotechnology

Hemostemix Inc. is a Canada-based autologous stem cell therapy company. The Company has developed, patented, and is scaling a patient’s blood-based stem cell therapeutics platform, which includes angiogenic cell precursors, neuronal cell precursors and cardiomyocyte cell precursors. The Company holds 87 patents on the derivation of three stem cell lineages from the patient’s blood, including angiogenic cell precursors (ACP-01), neuronal cell precursors, and cardiomyocyte cell precursors. ACP-01, its lead clinical-stage candidate, is an autologous cell therapy for the treatment of critical limb ischemia. ACP-01 is in a Phase 2 clinical trial in Canada and the United States. Its technology includes methods for collecting the synergetic cell population and manufacturing a personalized regenerative therapy that can be administered to a patient within seven days of the initial cell collection. Its subsidiaries include Kwalata Trading Limited, Hemostemix Ltd. and PreCerv Inc.

TSXV:HEM - Post by User

Hemostemix Inc > ACP-01 Midpoint Analysis

<< Previous

Bullboard Posts

Next >>

Comment by WalterTheDawgon Aug 12, 2022 5:52pm

176 Views

Post# 34893012

RE:RE:RE:RE:RE:RE:ACP-01 Midpoint Analysis

Also if I were Aspire and knew I had put out misleading info for which i could be held liable I would definitely hold on to the evidence and have any settlement include a clause stating i can't be sued afterwards for any interpretation i previously made public. I mean they did a lot of shady sh1t so I wouldn't put it past them and they also said in that NR that they delivered a copy of that midpoint analysis to hemostemix which Thomas declared under oath that they were never sent so who knows what kind of shenannigans they were up to

<< Previous

Bullboard Posts

Next >>

Unsung profits: Three microcap stocks with a strong case for value